Holen Sie sich die Stockscreener-App
8.34
16.01%
-1.59
Schlusskurs vom Vortag:
$9.93
Offen:
$9.65
24-Stunden-Volumen:
2.94M
Relative Volume:
2.14
Marktkapitalisierung:
$70.99M
Einnahmen:
$120.77M
Nettoeinkommen (Verlust:
$32.69M
KGV:
2.8615
EPS:
2.9146
Netto-Cashflow:
$-50.94M
1W Leistung:
+70.20%
1M Leistung:
+66.47%
6M Leistung:
-29.38%
1J Leistung:
+12.40%
1-Tages-Spanne:
$7.85
$9.93
1-Wochen-Bereich:
$4.63
$12.45
52-Wochen-Spanne:
$3.92
$19.14
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Firmenname
Atara Biotherapeutics Inc
Sektor
Branche
Telefon
805-623-4211
Adresse
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
8.34 | 70.99M | 120.77M | 32.69M | -50.94M | 2.9146 |
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 109.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
714.89 | 74.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.17 | 48.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.05 | 39.39B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
312.12 | 32.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-13 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-11-09 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-11-09 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-07-20 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-07-13 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-07-13 | Herabstufung | Stifel | Buy → Hold |
| 2022-05-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-05-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-12-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-30 | Eingeleitet | Evercore ISI | Outperform |
| 2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-23 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-09-27 | Herabstufung | Goldman | Neutral → Sell |
| 2019-09-16 | Herabstufung | Jefferies | Buy → Hold |
| 2019-06-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2019-05-30 | Eingeleitet | ROTH Capital | Buy |
| 2019-05-23 | Eingeleitet | Stifel | Buy |
| 2019-01-23 | Eingeleitet | Mizuho | Buy |
| 2018-04-10 | Eingeleitet | JP Morgan | Overweight |
| 2018-03-16 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-05 | Bestätigt | Jefferies | Buy |
| 2018-02-28 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-01-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Atara Biotherapeutics Inc Aktie (ATRA) Neueste Nachrichten
ATRA Upgraded by Canaccord Genuity -- Price Target Raised to $13 - GuruFocus
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Point72 (ATRA) holds 6.2% of Atara Biotherapeutics as of May 7, 2026 - Stock Titan
ATRA Shareholders Have Opportunity to Lead Atara Biotherapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
ATRA Shareholder Alert: Investors With Losses May Seek to - GlobeNewswire
CCORF Upgrades Atara Biotherapeutics(ATRA.US) to Buy Rating, Raises Target Price to $13 - Moomoo
MSN Money - MSN
Insider selling 1,405,000 ATRA shares (NASDAQ: ATRA) - Stock Titan
Atara Biotherapeutics | SCHEDULE 13G/A: Others - Moomoo
EcoR1 Group (NASDAQ: ATRA) reports ~17% holdings in Atara Biotherapeutics - Stock Titan
Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) - Quantisnow
Atara Biotherapeutics Inc. (ATRA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile
Atara surges after FDA meeting on cell therapy (ATRA:NASDAQ) - Seeking Alpha
DEADLINE ALERT for ATRA, COTY, SMCI, IBRX: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions - GlobeNewswire Inc.
Atara Biotherapeutics stock surges on FDA resubmission guidance - Investing.com
Atara partner discusses path for tab-cel resubmission with FDA By Investing.com - Investing.com South Africa
Bronstein, Gewirtz & Grossman LLC Urges Atara - GlobeNewswire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
FDA Resubmission Path for Tab-cel Keeps Atara’s (ATRA) Regulatory Timeline Alive - Yahoo Finance
ATRA Stock Surges As Traders Pile Into Biotech Momentum - StocksToTrade
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain OfficersATRA - PR Newswire
Atara says PFP had productive meeting with FDA - TipRanks
Atara Biotherapeutics Gains Clearer FDA Path for Tab-cel - TipRanks
Atara Biotherapeutics stock surges on FDA resubmission guidance By Investing.com - Investing.com Australia
ATRA Stock Pops As Traders Zero In On Volatile Spike - timothysykes.com
Atara partner discusses path for tab-cel resubmission with FDA - Investing.com
Atara Biotherapeutics provides regulatory update on tabelecleucel - marketscreener.com
Atara Biotherapeutics, FDA agrees single-arm study with historical control could support tab‑cel BLA resubmission - TradingView
Atara Biotherapeutics (ATRA) gains FDA guidance on tab-cel resubmission for EBV+ PTLD - Stock Titan
Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel - Business Wire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit - Barchart.com
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATRA DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 - ChartMill
ATRA DEADLINE NOTICE: Atara Biotherapeutics, Inc. Investors Encouraged to Contact Kirby McInerney LLP By May 22, 2026 - ACCESS Newswire
ATRA CLASS ACTION REMINDERGet in Touch With Robbins LLP Today For Information About Your Against Atara Biotherapeutics, Inc. - ACCESS Newswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile
Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until May 22nd to Seek Lead Plaintiff Role in Class Action Lawsuit - lincolnjournal.com
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA - ChartMill
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Portnoy Law Firm Announces Class Action on Behalf of Atara Biotherapeutics, Inc. Investors - GlobeNewswire
ATRA Q1'26 Earnings: EPS estimate is (0.33) USD - TradingView
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile
Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) - GlobeNewswire
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATRA Stock Price, Quote & Chart | ATARA BIOTHERAPEUTICS INC (NASDAQ:ATRA) - ChartMill
ROSEN, Global Investor Counsel, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
2026-05-03 | ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! | NDAQ:ATRA | Press Release - Stockhouse
ROSEN, LEADING INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure ... - Black Hills Pioneer
Finanzdaten der Atara Biotherapeutics Inc-Aktie (ATRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Atara Biotherapeutics Inc-Aktie (ATRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Panacea Innovation Ltd | 10% Owner |
Mar 17 '26 |
Option Exercise |
0.00 |
259,163 |
26 |
307,899 |
| Grant-Huerta Yanina | Chief Accounting Officer |
Mar 02 '26 |
Sale |
5.08 |
2,104 |
10,691 |
31,750 |
| Nguyen AnhCo | President and CEO |
Mar 02 '26 |
Sale |
5.09 |
2,996 |
15,237 |
61,978 |
11.97%
3.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):